TY  - JOUR
AU  - Pérez, Víctor
AU  - Salavert, Ariana
AU  - Espadaler, Jordi
AU  - Tuson, Miquel
AU  - Saiz-Ruiz, Jerónimo
AU  - Sáez-Navarro, Cristina
AU  - Bobes, Julio
AU  - Baca-García, Enrique
AU  - Vieta, Eduard
AU  - Olivares, José M
AU  - Rodriguez-Jimenez, Roberto
AU  - Villagrán, José M
AU  - Gascón, Josep
AU  - Cañete-Crespillo, Josep
AU  - Solé, Montse
AU  - Saiz, Pilar A
AU  - Ibáñez, Ángela
AU  - de Diego-Adeliño, Javier
AU  - AB-GEN Collaborative Group
AU  - Menchón, José M
PY  - 2017
DO  - 10.1186/s12888-017-1412-1
UR  - http://hdl.handle.net/10668/11405
T2  - BMC psychiatry
AB  - A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for drug therapy guidance. Patients...
LA  - en
KW  - Antidepressant response
KW  - Depression
KW  - Pharmacogenetics
KW  - Precision medicine
KW  - Randomized clinical trial
KW  - Adult
KW  - Antidepressive Agents
KW  - Depressive Disorder, Major
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Pharmacogenomic Testing
KW  - Treatment Outcome
TI  - Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
TY  - research article
VL  - 17
ER  -